Stephen E. Buxser, Ph.D.

Stephen E. Buxser, Ph.D.

“Changes in the pharmaceutical industry are driven by an explosion of biomedical information.  Unprecedented cooperation among academicians, government agencies and the business community is needed to redefine and energize emerging business and research models.”

Print this page

Analyst Stephen E. Buxser, Ph.D., applies his more than 20 years of experience in biochemistry, cell biology, and microbiology to advise pharmaceutical companies on drug development. With an intensive background in design and implementation of statistical data analysis methods and the use of biochemical kinetics to explore mechanisms of action, Dr. Buxser assists drug developers in areas that include small molecules, proteins, cells in culture, and small animal studies. His experience in both large and small pharmaceutical companies provides broad perspective to help build the bridges needed to combine the innovation of the smaller companies with the resources of the larger companies. From 2003 to 2008, Dr. Buxser was a principal and founder of a contract and basic research biotech company engaged in drug discovery and development. His primary responsibility was the company’s intellectual property and basic research programs, focusing on development of new classes of antibacterial drugs. In the lab he supervised senior scientists and associates, and outside the lab he implemented new intellectual property programs.

Previously, Dr. Buxser held progressively responsible research positions in the Upjohn/Pharmacia Company where he designed, implemented, and led biological research for three major projects, directly supervising a multifunction laboratory for assay design in biochemistry and cell biology and implementing assays in drug discovery. He has extensive experience in the development of kinase and antimicrobial assays, and has applied kinetics to studies ranging from enzymology to eukaryotic and prokaryotic cell biology and pharmacokinetics. In the area of statistical analysis, Dr. Buxser derived and applied equations appropriate to kinetic models adjusted for particular experimental conditions to maximize mechanistic information and assure the quality of the data. He also designed computer programs that automate the determination of statistically defined hits in high-throughput assays and developed new methods for analyzing HTS data on fundamental theoretical statistical principles.

Dr. Buxser earned his Ph.D. at the University of Cincinnati Medical School and held a post-doctoral fellowship at the University of Massachusetts Medical School’s Department of Biochemistry. He also holds a master’s degree in bacteriology from the University of Wisconsin. Dr. Buxser is a member of Sigma Xi, the American Association for the Advancement of Science, and the Federation of the American Societies for Experimental Biology, American Society for Biochemistry and Molecular Biology. He has been published in a series of journals, including Analytical Biochemistry, The Journal of Immunogenics, The Journal of Immunology, and The Journal of Neurochemistry.


  • Ph.D., Microbiology, University of Cincinnati Medical School
  • Post-Doctoral Fellow, Department of Biochemistry, University of Massachusetts Medical School
  • M.S., Bacteriology, University of Wisconsin
  • B.S., Microbiology, Ohio State University
  • Member, Federation of the American Societies for Experimental
  • Biology, American Society for Biochemistry and Molecular Biology
  • Member, Sigma Xi
  • Member, American Association for the Advancement of Science


  • Tong, DDM, S Buxser, and TJ VIdmar, “Application of a mixture model for determining the cutoff threshold for activity in high-throughput screening”, Comp. Stat. Data Anal, 51: 4002-4012, 2007
  • Buxser, SE, and DL Chapman, “Use of mixture distributions to deconvolute the behavior of ‘hits’ and controls in high-throughput screening data”, Anal.  Biochem, 361: 197-209, 2007
  • Buxser, SE, and Vroegop, SM, “Calculating the probability of detection for inhibitors in enzymatic or binding reactions in high-throughput screening”, Anal. Biochem, 340: 1-13, 2005
  • Chapman, DL and Buxser, SE, “Effects of membrane partitioning and other physical chemical properties on the apparent potency of ‘membrane active’ compounds evaluated using red blood cell lysis assays”, Anal. Biochem, 303: 153-166, 2002
  • Vroegop SM, Chapman DL, Decker DE, Galinet LA, Brideau RJ, Ready KA, Dunn CJ, Buxser SE, “Pharmacokinetic properties, induction of interferon, and efficacy of selected 5-halo-6-phenyl pyrimidinones, bropirimine analogues, in a model of severe experimental autoimmune encephalomyelitis”, Intl. J. Immunopharm, 21: 647-662, 1999
  • Buxser SE, Sawada, G Raub TJ, “Analytical and numerical techniques for the evaluation of free radical damage in cultured cells using imaging cytometry and fluorescent indicators”, Methods Enzymol, 300: 256-275, 1999
  • Sawada GA, Raub TJ, Decker DE, Buxser SE, “Analytical and numerical techniques for the evaluation of free radical damage in cultured cells using scanning laser microscopy”,  Cytometry, 25: 254-262, 1996
  • Decker, DE, Vroegop, SM and Buxser, SE, “Localization of damage induced by reactive oxygen species in cultured cells”, Free Radical Biology & Medicine, 18:141-151, 1995
  • Decker, DE, Vroegop, SM and Buxser, SE, “Inhibition of oxidative insult in cultured cells by a novel 6-chromanol-containing antioxidant”, Biochemical Pharmacology  50:1063-1070, 1995
  • Decker, DE, Vroegop, SM, Goodman, TG, Peterson, T and Buxser, SE, “Kinetics and thermodynamics of emulsion delivery of lipophilic antioxidants to cells in culture”, Chem. Phys. Lipids.  76:7-25, 1995
  • Raffioni, S, Buxser, SE and Bradshaw, RA, “The receptors for nerve growth factor and other neurotrophins”, Ann. Rev. Biochem. 62: 823-850, 1993
  • Vroegop, SM, Crumm, E and Buxser, SE, “Characterization of ultra-high affinity monoclonal antibodies with a dimeric, symmetrical antigen: inhibition of the receptor recognition site of nerve growth factor”, Molecular Immunol. 29: 411 423, 1992
  • Buxser, SE, Vroegop, SM, Decker, DE, Hinzmann, J, Poorman, R, Thomsen, DR, Steir, M, Abraham, I, Greenberg, BD, Hatzenbuhler, NT, Shea, M, Curry, KA and Tomich, C-SC, “Single-step purification and biological activity of human nerve growth factor produced from insect cells”, J. Neurochem, 56: 1012-1018, 1991
  • Yagi, J, Baron, J, Buxser, SE and Janeway CA, “Bacterial proteins that mediate the association of a defined subset of T cell receptor: CD4 complexes with class II MHC”, J. Immunol. 144: 892-901, 1990
  • Janeway, Jr. CA, Yagi, J, Conrad, PJ, Katz, ME, Jones, B, Vroegop, SM and Buxser, SE, “T Cell responses to Mls and to bacterial proteins that mimic its behavior”, Immunologic. Rev. 107: 61-88, 1989
  • Buxser, SE and Vroegop, SM, “Staphylococcal enterotoxin B stimulation of Balb/c lymphocyte mitogenesis and potential relationship to the Mls response”, J. Immunogenetics 15: 153-159, 1988
  • Puma, P, Buxser, SE, Watson, L, Kelleher, DJ and Johnson, GL, “Purification of the receptor for nerve growth factor from A875 melanoma cells by affinity chromatography”, J. Biol. Chem. 258: 3370-3375, 1983
  • Buxser, SE, Bonventre, PF and Archer, DL, “Specific receptor binding of staphylococcal enterotoxins by murine splenic lymphocytes”, Infect. Immun. 33:827 833, 1981

Go Back Back To Top


Technology Transfer Problems and Perspectives: An Examination of Recent Literature

The Revolution in Next Generation Nucleic Acid Sequencing: How is it profoundly changing biology and medicine?


Custom Briefing Report: Development of new assays or techniques involving nucleic acid detection of viruses


Stephen E. Buxser, Ph.D. Nerac
  • One Technology Drive
  • Tolland, CT 06084